Christopher Hourigan, DM, DPhil, FACP, FRCP, obtained his medical degree and DPhil in human immunology from Oxford University, Oxford, UK. After completing his residency at Guy’s and St. Thomas’ Hospital, London, UK, and the Johns Hopkins Bayview Medical Center, Baltimore, MD, Dr Hourigan joined the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, where he completed his fellowship in medical oncology and his postdoctoral research fellowship in the immunology and immunotherapy research program.
Dr Hourigan joined the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Bethesda, MD, in 2012 as an Assistant Clinical Investigator and was then appointed as an Investigator in 2015. Dr Hourigan is currently Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Bethesda, MD.
Speaking on AML therapeutics and transplantation
Dr Hourigan’s research focuses on the prevention, detection, and treatment of acute myeloid leukemia (AML) relapse. The cutting-edge research undertaken by Dr Hourigan’s lab include clinical trials of high sensitivity diagnostics and immunotherapy. Dr Hourigan’s most recent involvements include a publication on azacitidine maintenance after transplantation for AML as well as a Phase I/II trial investigating pembrolizumab and decitabine for refractory/relapsed AML.